Connecticut Man Diagnosed with Alzheimer’s Sees Hope in New Drug

UPDATE: A Connecticut attorney diagnosed with early onset Alzheimer’s disease is finding hope in groundbreaking treatment options as his story unfolds. Lee Ross, 61, has taken a decisive step forward after receiving a diagnosis that shocked his family and changed his life.

Ross first noticed troubling signs when he struggled to find words and finish sentences, prompting him to seek medical answers. “I just knew that something wasn’t right,” he shared, emphasizing his resolve to find a diagnosis despite initial suggestions that his issues were linked to anxiety or lack of sleep. After rigorous testing and brain scans, Ross received the diagnosis earlier this year.

The devastating news led to a swift life change for Ross, who had worked as the legislative director at the state judicial branch. “All of a sudden, I am an Alzheimer’s patient,” he recalled, revealing the emotional weight of his condition. However, his situation took a hopeful turn when he learned about the drug Leqembi, developed by Eisai in partnership with Biogen. This medication is designed to slow the disease’s progression by reducing the buildup of amyloid plaques in the brain.

“I didn’t hesitate for a second,” Ross said regarding his decision to use Leqembi. “The benefits of this far, far outweigh the risks.”

Ross, who has been married to his wife Doreen for 37 years, discussed the treatment with his family before proceeding. He emphasized the importance of taking charge of one’s health, especially in the face of a daunting diagnosis. “If I couldn’t use this medication… it helps remove some of the plaque from your brain,” he explained, highlighting the critical nature of early intervention.

The potential side effects of Leqembi include headaches, confusion, and dizziness, but Ross remains optimistic. He did experience some brain swelling after starting the treatment, leading him to temporarily stop. However, he has resumed the medication, stating that “the alternative is just not an option.”

According to the Alzheimer’s Association, there are approximately 80,000 people living with Alzheimer’s in Connecticut alone, and around 250,000 in the U.S. diagnosed with younger onset Alzheimer’s, which affects individuals under 65. These statistics underscore the urgency for early diagnosis and treatment.

Kristen Cusato, a director at the Alzheimer’s Association Connecticut, praised Ross for his proactive approach. His story serves as a powerful example of the importance of early testing and awareness of available treatments. “A lot of people have a hard time getting a diagnosis,” Cusato noted. “Education is key when it comes to this disease.”

In addition to his treatment journey, Ross is actively participating in community efforts, including forming a team for the upcoming Walk to End Alzheimer’s in Greater Hartford on October 19, 2023. The event aims to raise funds and awareness for Alzheimer’s research and support, with a ceremony beginning at 10 a.m. at Rentschler Field.

As he continues his treatment, Ross remains committed to sharing his story, hoping to encourage others to seek help early. “By doing that, I found this early enough,” he said. “I just felt, if I could do something, maybe they would think ‘I should get some testing.’”

For anyone experiencing early signs of Alzheimer’s, the Alzheimer’s Association offers a 24/7 helpline at 1-800-272-3900 and additional resources at alz.org. Awareness and education could lead to earlier interventions, ultimately improving the quality of life for many affected by this disease.

As research continues to evolve, Ross’s journey shines a light on the importance of hope and action in the face of Alzheimer’s disease.